Department of Nephrology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Nephron. 2021;145(4):415-427. doi: 10.1159/000513009. Epub 2021 Apr 19.
Atypical hemolytic uremic syndrome (aHUS) is a rare but critical illness. To this date, few studies have reported on the disease in Chinese children.
We studied a Chinese pediatric cohort to delineate the clinical characteristics, genotypes, and prognosis. Ninety-one patients with aHUS were enrolled in this study.
Fifty-nine children (64.8%) had anti-complement-factor-H autoantibody-associated aHUS (anti-CFH aHUS). Of these children, 21 (46.7%) had complement factor-H-related protein 1 (CFHR1) homozygous deletion, and most patients with CFHR1 homozygous deletion also had complement factor-H-related protein 3 (CFHR3) homozygous deletions (76.2%). Using gene sequencing of 15 candidate genes, we identified 14 genetic variants in 46 aHUS patients, including 5 pathogenic or like pathogenic variants and 9 variants of uncertain significance. The average follow-up time was 46.1 ± 28 months. Among patients with anti-CFH aHUS, there was a correlation between CFHR1 homozygous deletion and patients with persistent proteinuria (odds ratio [OR] 6.954, 95% confidence interval [CI] 1.033-46.821, p = 0.046). As of the last follow-up, ESRD or deaths occurred in 3.6% of the children with anti-CFH aHUS and 26.7% of children with aHUS who were negative for anti-CFH.
Anti-complement-factor-H antibody positivity is the main cause of morbidity in Chinese children with aHUS. There may be a correlation between CFHR1 homozygous deletion and persistent proteinuria. Comprehensive assessment of anti-CFH antibodies and genetic variants is essential for the management of aHUS children.
非典型溶血尿毒综合征(aHUS)是一种罕见但严重的疾病。迄今为止,很少有研究报告中国儿童的这种疾病。
我们研究了一个中国儿科队列,以描绘其临床特征、基因型和预后。本研究纳入了 91 例 aHUS 患儿。
59 例患儿(64.8%)存在抗补体因子-H 自身抗体相关性 aHUS(抗-CFH aHUS)。其中 21 例(46.7%)患儿存在补体因子-H 相关蛋白 1(CFHR1)纯合缺失,且大多数 CFHR1 纯合缺失的患者也存在补体因子-H 相关蛋白 3(CFHR3)纯合缺失(76.2%)。通过对 15 个候选基因进行基因测序,我们在 46 例 aHUS 患儿中发现了 14 种遗传变异,包括 5 种致病性或类似致病性变异和 9 种意义不明的变异。平均随访时间为 46.1±28 个月。在抗-CFH aHUS 患者中,CFHR1 纯合缺失与持续性蛋白尿之间存在相关性(比值比[OR]6.954,95%置信区间[CI]1.033-46.821,p=0.046)。截至最后一次随访,抗-CFH aHUS 患儿中 3.6%发生终末期肾病或死亡,抗-CFH 阴性的 aHUS 患儿中 26.7%发生终末期肾病或死亡。
抗补体因子-H 抗体阳性是中国儿童 aHUS 的主要发病原因。CFHR1 纯合缺失可能与持续性蛋白尿相关。全面评估抗-CFH 抗体和遗传变异对 aHUS 患儿的管理至关重要。